- Men, Make Health Your Goal This Year
- Child Car Seat Safety Tip: Skip Puffy Winter Coats
- UK Prime Minister Says British COVID Variant May Be More Deadly
- FDA Approves First Once-a-Month HIV Therapy
- Half of Americans Still Not Wearing Masks When Out in Public: Poll
- For Maximum Effectiveness, De-Stress and Get Healthy Before Your COVID Shot
- AHA News: Anxiety Is Linked With Smoking – But How Is Still Hazy
- Biden Warns of 500,000 COVID Deaths by February
- Health Highlights: Jan. 22, 2021
- For Rising Number of People, Obesity Is a Literal Headache
Drug Approved for Inherited Blood Disorder
WEDNESDAY, Jan. 23Exjade (deferasirox) has been approved by the U.S. Food and Drug Administration to remove excess iron in the blood among people with a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
Too much iron in the blood can damage vital organs, the agency said Wednesday in a news release.
Thalassemia typically leads to the production of fewer red blood cells and less hemoglobin, a protein that carries oxygen throughout the body. NTDT is a milder form of thalassemia that unlike other forms, does not require frequent blood transfusions. Thalassemia affects about 1,000 people in the United States, the FDA said.
The FDA previously approved Exjade to treat chronic iron overload among people who require blood transfusions.
The drug is produced by Novartis, East Hanover, N.J.
More information
The U.S. National Heart Lung and Blood Institute has more about thalassemia.
Source: HealthDay
